Beyond Air, Inc. (XAIR) Bundle
A Brief History of Beyond Air, Inc. (XAIR)
Foundation and Early Development
Foundation and Early Development
Beyond Air, Inc. (NASDAQ: XAIR) was established in 2011, focusing on the development of medical therapies utilizing nitric oxide (NO) for various respiratory conditions. The company originated from research conducted at the University of California, Berkeley, and is headquartered in Garden City, New York.
Public Offering
In December 2020, Beyond Air completed its initial public offering (IPO), raising approximately $32 million at a price of $10 per share. The IPO granted it access to capital for advancing its clinical programs and expanding its market reach.
Clinical Trials and Product Pipeline
Beyond Air's key product is its non-invasive nitric oxide delivery system, known as the LungFit system. As of 2023, key milestones in its clinical trial phases are listed as follows:
| Trial Phase | Indication | Completion Date | Participants | Status |
|---|---|---|---|---|
| Phase 3 | COVID-19 | December 2023 | 300 | Recruiting |
| Phase 2 | Cystic Fibrosis | September 2023 | 150 | Completed |
| Phase 1 | Chronic Obstructive Pulmonary Disease (COPD) | March 2023 | 75 | Completed |
Financial Performance
As of the third quarter of 2023, Beyond Air reported financial metrics that reflect its ongoing developmental strategies:
| Metric | Q3 2023 | Q3 2022 |
|---|---|---|
| Revenue | $1.1 million | $0.3 million |
| Net Loss | $(8.6) million | $(6.5) million |
| Cash Position | $22.5 million | $15 million |
Strategic Partnerships
Beyond Air has formed several strategic partnerships to enhance its research and development capabilities. Notably, in early 2023, they collaborated with Curevac AG for advancing respiratory treatments, leveraging their mRNA technology.
Market Impact and Future Prospects
As of 2023, Beyond Air's market capitalization stands at approximately $180 million, reflecting investor confidence in its potential products. The company is positioned to expand its influence in the pulmonary and respiratory therapy markets, targeting annual growth rates of over 15% in the next five years.
A Who Owns Beyond Air, Inc. (XAIR)
Current Ownership Structure
As of the latest filings, Beyond Air, Inc. (XAIR) has a diverse ownership structure comprising institutional investors, individual shareholders, and insider ownership.
| Ownership Type | Percentage Ownership |
|---|---|
| Institutional Investors | 45% |
| Insider Ownership | 10% |
| Retail Investors | 45% |
Major Institutional Shareholders
The following table outlines the major institutional shareholders of Beyond Air, Inc., highlighting their respective ownership percentages as of the most recent quarter.
| Institution | Ownership Percentage | Shares Owned |
|---|---|---|
| BlackRock, Inc. | 10.5% | 1,250,000 |
| Vanguard Group, Inc. | 7.2% | 850,000 |
| State Street Corporation | 6.0% | 700,000 |
| Wellington Management Co. LLP | 5.5% | 650,000 |
Insider Ownership
Insider ownership includes key executives who hold shares in Beyond Air, Inc. The following table provides insight into the leading insiders and their holdings.
| Name | Position | Shares Owned | Ownership Percentage |
|---|---|---|---|
| President/CEO | Adam L. Koppel | 300,000 | 1.5% |
| Chief Financial Officer | Richard A. Larkin | 150,000 | 0.75% |
| Director | Susan M. Anderson | 100,000 | 0.5% |
Recent Stock Performance
As of October 2023, the stock performance of Beyond Air, Inc. is as follows:
| Metric | Value |
|---|---|
| Current Stock Price | $3.20 |
| Market Cap | $100 million |
| 52-Week High | $4.50 |
| 52-Week Low | $2.10 |
Shareholder Meetings and Votes
Shareholder meetings are critical for voting on various corporate matters. Below are some key details from recent meetings:
| Meeting Date | Voting Items | Votes For | Votes Against |
|---|---|---|---|
| June 15, 2023 | Election of Board Members | 90% | 10% |
| June 15, 2023 | Approval of Executive Compensation | 85% | 15% |
Market Dynamics
The market dynamics affecting Beyond Air, Inc. include competition and overall market trends in the biotech sector. The following table summarizes key market data relevant to the company's standing.
| Metric | Value | Industry Average |
|---|---|---|
| R&D Expenditure | $20 million | $15 million |
| Gross Margin | 70% | 60% |
Beyond Air, Inc. (XAIR) Mission Statement
Corporate Overview
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage company, focuses on developing and commercializing innovative therapies for respiratory conditions through its proprietary nitric oxide platform. The overarching mission of Beyond Air is to develop safer and effective solutions to improve patient outcomes by providing revolutionary therapies.
Core Values
- Innovation: Commitment to pioneering advancements in respiratory therapies.
- Integrity: Upholding the highest ethical standards in all endeavors.
- Collaboration: Fostering partnerships to enhance research and development capabilities.
- Patient-Centricity: Prioritizing patient needs and safety in all aspects of the business.
Financial Overview
As of the latest financial reports, Beyond Air, Inc. has the following key figures:
| Fiscal Year | Revenue ($ Millions) | Net Income ($ Millions) | R&D Expenses ($ Millions) | Cash & Cash Equivalents ($ Millions) |
|---|---|---|---|---|
| 2020 | 0.00 | (10.12) | 5.65 | 15.25 |
| 2021 | 0.00 | (12.34) | 8.40 | 18.75 |
| 2022 | 0.00 | (13.86) | 11.50 | 22.10 |
| 2023 (Projected) | 0.00 | (15.00) | 13.00 | 25.00 |
Key Products and Pipeline
The primary focus of Beyond Air is the development of its lead product, AIRNO, a nitric oxide delivery system tailored for patients with respiratory conditions. The pipeline includes:
- AIRNO: Treatment for asthma and other respiratory diseases.
- Additional indications: Investigating applications in cystic fibrosis and other pulmonary conditions.
Market Opportunity
As per the latest market analysis, the global respiratory disease market is expected to exceed $40 billion by 2025, with a CAGR of around 7.5% from 2020 to 2025. Beyond Air aims to capture a significant share of this growing market through its innovative solutions.
Strategic Partnerships
Beyond Air engages in strategic alliances to bolster its research and marketing capabilities. Recent collaborations include:
- Partnership with Leading Hospitals: Enhancing clinical trials for AIRNO.
- Collaboration with Research Institutions: Development of innovative applications of nitric oxide.
Investment and Future Outlook
As of recent funding rounds, Beyond Air has raised approximately $50 million in capital to advance its clinical trials and product development. The future outlook remains optimistic with anticipated product launches expected to position the company favorably within the competitive landscape.
Conclusion
Through its unwavering commitment to innovation and patient care, Beyond Air, Inc. continues to strive towards making a substantial impact in the field of respiratory health.
How Beyond Air, Inc. (XAIR) Works
Company Overview
Company Overview
Beyond Air, Inc. (XAIR) is a clinical-stage medical device and biopharmaceutical company. It focuses on the development of a proprietary technology platform known for delivering nitric oxide (NO) gas therapeutically for various respiratory conditions. The company is headquartered in Great Neck, New York.
Business Model
Beyond Air employs a dual revenue model that includes:
- Sale of medical devices for NO delivery
- Licensing agreements for pharmaceutical applications
Technology Platform
The company’s main product, the lung delivery system, utilizes a novel method of delivering NO to patients suffering from conditions such as:
- COVID-19
- Asthma
- Cystic Fibrosis
This system is designed to provide targeted treatment while minimizing systemic exposure.
Market Opportunity
According to a recent report, the global nitric oxide market is expected to grow from $1.0 billion in 2022 to $1.8 billion by 2028, with a compound annual growth rate (CAGR) of approximately 10%.
Financial Snapshot
As of the second quarter of 2023, Beyond Air reported:
- Revenue: $2.1 million
- Net Loss: $8.2 million
- Cash and Cash Equivalents: $15.4 million
Recent Developments
In August 2023, Beyond Air announced the completion of a $10 million private placement to support ongoing clinical trials and operational expenses.
Clinical Trials
Beyond Air is currently conducting multiple clinical trials:
- Phase 2 Trial for COVID-19: Estimated enrollment of 200 patients
- Phase 3 Trial for Asthma: Aiming for 300 patients in the U.S. and EU
Research and Development
The company has invested approximately $5 million in R&D for the fiscal year 2023, focusing on enhancing the efficacy and delivery mechanisms of its nitric oxide therapies.
Partnerships and Collaborations
In 2023, Beyond Air signed a partnership with a leading healthcare provider to co-develop NO delivery systems for pediatric patients, enhancing its market reach.
Competitive Landscape
Beyond Air faces competition from several companies in the respiratory treatment sector. Key players include:
| Company Name | Market Cap (as of Q3 2023) | Focus Area |
|---|---|---|
| OxySure Therapeutics | $50 million | Oxygen delivery systems |
| Auris Medical | $25 million | Otolaryngological solutions |
| Proterris | $30 million | Antiviral treatments |
Future Outlook
Beyond Air’s strategic initiatives aim to capitalize on the increasing demand for NO therapies. Analyst projections indicate potential revenue growth post-2025, contingent on successful clinical trial outcomes and product approvals.
How Beyond Air, Inc. (XAIR) Makes Money
Product Revenue
Beyond Air generates revenue primarily through the sale of its proprietary medical devices and therapies. The company focuses on the development of nitric oxide therapies for a range of respiratory conditions, which are crucial for their financial performance.
Partnerships and Collaborations
The company engages in strategic partnerships that facilitate market penetration and product development. For instance, Beyond Air entered into a partnership with Medtronic to enhance its market reach, generating potential revenue streams from shared sales and collaboration agreements.
Royalty Income
Beyond Air also benefits from royalty income through licensing agreements related to its technology. The company has secured deals that allow it to earn 10% to 15% royalties based on generated revenues from licensed products in various markets.
Table of Financial Performance
| Year | Revenue ($ million) | Net Income ($ million) | Gross Margin (%) |
|---|---|---|---|
| 2020 | 0.45 | (11.32) | 30% |
| 2021 | 0.95 | (9.80) | 35% |
| 2022 | 1.25 | (7.50) | 40% |
| 2023 (Projected) | 2.50 | (5.00) | 45% |
Research Grants
Beyond Air applies for research grants which contribute to its funding. The company has received grants totalling approximately $1.5 million from various governmental health organizations aimed at supporting the development of its nitric oxide delivery systems.
Market Expansion
Entering new markets is a crucial aspect of Beyond Air's revenue strategy. The company is expanding into Europe and Asia, which are forecasted to increase its market share significantly. The projected sales growth in these territories could amount to $10 million by 2025.
Table of Market Expansion Opportunities
| Region | Projected Revenue ($ million) | Market Growth (%) |
|---|---|---|
| North America | 3.5 | 20% |
| Europe | 2.5 | 25% |
| Asia | 4.0 | 30% |
Direct Sales and E-commerce
Beyond Air has launched direct sales initiatives and e-commerce platforms to enhance customer access to its products, aiming for a revenue increase through direct sales channels, projected at $1 million annually.
Cost Management and Optimization
Efficient cost management strategies are implemented to ensure profitability as revenues grow. Cost reduction in manufacturing is projected to improve margins by 5% over the next year, further enhancing financial performance.
Beyond Air, Inc. (XAIR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support